Chimerix Announces First Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Chimerix Announces First Quarter Financial Results
May 11, 2015 12:37 PM EDT
Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Chimerix (NASDAQ: CMRX) to $50.00 (from $45.00), saying Brinci has broad utility.
Aschoff commented, "The Phase 3 SUPPRESS trial with brincidofovir for the prevention of cytomegalovirus (CMV) in hematopoietic cell transplant patients is nearly 95% enrolled, and we expect it to be fully enrolled (n=450) in the summer of 2015 and read out pivotal... More
May 11, 2015 7:31 AM EDT
Chimerix (NASDAQ: CMRX) reported Q1 EPS of ($0.54), $0.03 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $1.19 million.
For earnings history and earnings-related data on Chimerix (CMRX) click here.
...
More
